ASCO 2019 Drug targeting DNA damage response shows promise against cancers of anus and genitals

ASCO 2019: Drug targeting DNA damage response shows promise against cancers of anus and genitals

11:43 EDT 1 Jun 2019 | ecancermedicalscience

A precision medicine targeting a key protein which helps cancer cells to tolerate DNA damage has shown promising results in two clinical trials. The new findings demonstrate the safety of the drug, called SRA737, in a range of cancers and particular...

More From BioPortfolio on "ASCO 2019: Drug targeting DNA damage response shows promise against cancers of anus and genitals"